Advertisement

Galanthamine treatment in Alzheimer’s disease

  • P. Dal-Bianco
  • J. Maly
  • Ch. Wöber
  • C. Lind
  • G. Koch
  • J. Hufgard
  • I. Marschall
  • M. Mraz
  • L. Deecke
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 33)

Summary

18 patients who had fullfilled the NINCDS-ADRDA criteria for “possible AD” took part in a clinical study to evaluate the effect of the cholinesteraseinhibitor Galanthamine, 30 mg/day. Neuropsychological and social parameters were rated. This open clinical pilot-study showed no statistic significant change in neuropsychological test-results. However after 1 year treatment 6 patients are still taking the drug. According to their care-persons there was a positive changes in competence of everyday-routine and/or in the emotional situation.

Keywords

Cholinergic Neuron Senile Dementia Memory Score Emotional Situation Choline Acetyl 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Coyle JT, Price DL, DeLong MR (1983) Alzheimer’s disease: a disorder of cortical cholingergic innervation. Science 219: 1184–1190PubMedCrossRefGoogle Scholar
  2. Dal-Bianco P, Maly J, Deecke L (1988) THA-Therapie bei Patienten mit seniler Demenz vom Alzheimer-Typ. Wien Klin Wochenschr 100 (12): 415Google Scholar
  3. Davies P, Maloney AJF (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet ii: 1403Google Scholar
  4. Davis KL, Mohs RC (1986) Cholinergic drugs in Alzheimer’s disease. N Engl J Med 315: 1286–1287PubMedCrossRefGoogle Scholar
  5. McKhann G, Drachman D, Folstein M, et al (1984) Clinical diagnosis of Alzheimer’s disease. Neurology 34: 939–944PubMedGoogle Scholar
  6. Perry EK, Tomlinson BE, Blessed G, et al (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2: 1457–1459PubMedCrossRefGoogle Scholar
  7. Summers WK, et al (1981) Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients. Biol Psychiatry 16 (2): 145PubMedGoogle Scholar
  8. Summers WK, Majovski LV, Marsh GM, et al (1986) Oral THA in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 315: 1241–1245Google Scholar
  9. Sweeney JE, Höhmann CF, Moran TH, Coyle JT (1988) A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice. Pharmacol Biochem Behav 31: 141–147PubMedCrossRefGoogle Scholar
  10. Thomsen T, Bickel U, Fischer JP, Kewitz H (1991) Tolerance and inhibition of cholinesterases by Galanthamine in healthy volunteers and Alzheimer patients (in apress)Google Scholar
  11. Westra P, et al (1986) Pharmacokinetics of galanthamine (a long-acting anticholinesterase drug) in anaesthetized patients. Br J Anaesth 58: 1303–1307PubMedCrossRefGoogle Scholar
  12. Whitehouse PJ, Price Dl, Clark AW, et al (1981) Alzheimer disease: evidence for selective loss of cholinergie neurons in the nucleus basalis. Ann Neurol 10: 122–126PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • P. Dal-Bianco
    • 1
  • J. Maly
    • 2
  • Ch. Wöber
    • 2
  • C. Lind
    • 2
  • G. Koch
    • 2
  • J. Hufgard
    • 2
  • I. Marschall
    • 2
  • M. Mraz
    • 2
  • L. Deecke
    • 2
  1. 1.Neurological University ClinicViennaAustria
  2. 2.Neurology University ClinicViennaAustria

Personalised recommendations